Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases
Quazim A. Alayo, Aava Khatiwada, Anish Patel, Maria Zulfiqar, Anas Gremida, Alexandra Gutierrez, Richard P. Rood, Matthew A. Ciorba, George Christophi, Parakkal Deepak
doi: https://doi.org/10.1101/2020.10.18.20214841
Quazim A. Alayo
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
2Department of Internal Medicine, St. Luke’s Hospital, Chesterfield, MO, USA
MD MSc MMScAava Khatiwada
3Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA
MDAnish Patel
4Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas, USA
DOMaria Zulfiqar
5Department of Radiology, Mallinckrodt Institute of Radiology, Washington University in Saint Louis, St. Louis, MO, USA
MDAnas Gremida
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
MDAlexandra Gutierrez
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
MD MPHRichard P. Rood
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
MDMatthew A. Ciorba
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
MDGeorge Christophi
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
6Department of Medicine, University of Central Florida, Orlando, FL, USA
MD PhDParakkal Deepak
1Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA
MBBS MSData Availability
N/A
Posted October 21, 2020.
Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases
Quazim A. Alayo, Aava Khatiwada, Anish Patel, Maria Zulfiqar, Anas Gremida, Alexandra Gutierrez, Richard P. Rood, Matthew A. Ciorba, George Christophi, Parakkal Deepak
medRxiv 2020.10.18.20214841; doi: https://doi.org/10.1101/2020.10.18.20214841
Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases
Quazim A. Alayo, Aava Khatiwada, Anish Patel, Maria Zulfiqar, Anas Gremida, Alexandra Gutierrez, Richard P. Rood, Matthew A. Ciorba, George Christophi, Parakkal Deepak
medRxiv 2020.10.18.20214841; doi: https://doi.org/10.1101/2020.10.18.20214841
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2915)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12709)
- Forensic Medicine (12)
- Gastroenterology (826)
- Genetic and Genomic Medicine (4566)
- Geriatric Medicine (414)
- Health Economics (726)
- Health Informatics (2912)
- Health Policy (1068)
- Hematology (385)
- HIV/AIDS (921)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (467)
- Neurology (4333)
- Nursing (234)
- Nutrition (636)
- Oncology (2261)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (498)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6914)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (436)
- Sports Medicine (383)
- Surgery (484)
- Toxicology (60)
- Transplantation (210)
- Urology (178)